together account for approximately 10% of the intrav enous dose. The binding of ciprofloxacin to serum proteins is 20 to 40%. Ciprofloxacin is an inhibitor of human cytochrome P450 1A2 (CYP1A2) mediated metabolism. Coadministration of ciprofloxacin with other drugs primarily metabolized by
Acetaminophen. Cinoxacin, The metabolism of Acetaminophen can be decreased when combined with Cinoxacin. Ciprofloxacin, The metabolism of Acetaminophen can be
ciprofloxacin increases ciprofloxacin Non-renal clearance of ciprofloxacin is mainly due to active trans-intestinal secretion and metabolism.
Warfarin. Ciprofloxacin, The serum concentration of Warfarin can be increased when it is combined with Ciprofloxacin. Cisapride, The metabolism of Warfarin
together account for approximately 10% of the intrav enous dose. The binding of ciprofloxacin to serum proteins is 20 to 40%. Ciprofloxacin is an inhibitor of human cytochrome P450 1A2 (CYP1A2) mediated metabolism. Coadministration of ciprofloxacin with other drugs primarily metabolized by
Ciprofloxacin inhibits the metabolism of caffeine with potential increase in Ciprofloxacin. In: Australian. Injectable Drugs Handbook [Internet]
Warfarin. Ciprofloxacin, The serum concentration of Warfarin can be increased when it is combined with Ciprofloxacin. Cisapride, The metabolism of Warfarin
Ciprofloxacin is partially metabolized in the liver by modification of the piperazinyl group to at least four metabolites which are N-acetyl ciprofloxacin, Oxo-ciprofloxacin, desethylene
ciprofloxacin will increase the level or effect of ramelteon by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor. Ciprofloxacin may decrease the metabolism of ramelteon; if ciprofloxacin is coadministered with ramelteon, monitor the patient closely for toxicity. ranolazine. ciprofloxacin and ranolazine both increase QTc interval.
[email protected]